Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose OPC-34712 for adults with acute schizophrenia
2011-002513-11Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole in schizophrenia (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change in Positive and Negative Syndrome Scale (PANSS) total score. Started Nov 2011; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-002513-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002513-11.